Prosensa Holding, a biotech engaged in the discovery and development of RNA-modulating therapeutics for the treatment of genetic disorders, announced terms for its IPO on Tuesday. The Leiden, Netherlands-based company plans to raise $60 million by offering 5 million shares at a price range of $11 to $13. At the midpoint of the proposed range, Prosensa Holding would command a market value of $408 million.
Prosensa Holding, which was founded in 2002 and booked $11 million in license and collaboration revenue for the 12 months ended March 31, 2013, plans to list on the NASDAQ under the symbol RNA. Prosensa Holding initially filed confidentially on April 16, 2013. J.P. Morgan, Citi and Leerink Swann are the joint bookrunners on the deal.
